Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression

• Published in: Cancer research (Chicago, Ill.) Vol. 54; no. 3; pp. 605 - 609
• Main Authors: Kim, T M, Benedict, W F, Xu, H J, Hu, S X, Gosewehr, J, Velicescu, M, Yin, E, Zheng, J, D'Ablaing, G, Dubeau, L
• Format: Journal Article
• Language: English
• Published: United States 01.02.1994
• Subjects: Alleles; Base Sequence; Carcinoma - genetics; Chromosomes, Human, Pair 13 - physiology; Cystadenoma - genetics; Epithelium - pathology; Female; Gene Deletion; Gene Expression - genetics; Genes, Retinoblastoma - genetics; Heterozygote; Humans; Immunohistochemistry; Molecular Sequence Data; Ovarian Neoplasms - chemistry; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Retinoblastoma Protein - analysis; Retinoblastoma Protein - genetics
• ISSN: 0008-5472

We examined the frequencies of loss of heterozygosity on chromosome 13 in 77 primary ovarian epithelial tumors subdivided into cystadenomas, tumors of low malignant potential, low grade carcinomas, and high grade carcinomas. Such losses were found in approximately 50% of high grade carcinomas but were not detected in any of the other tumor subtypes (P < 0.0001), suggesting a strong association between these abnormalities and the high grade carcinoma phenotype. The tumors were also examined for abnormalities in expression of the retinoblastoma susceptibility gene (RB). This was assessed by immunohistochemical staining of archival tumor sections with a polyclonal antibody directed against both the phosphorylated and the underphosphorylated forms of the RB protein. Most of the tumors, including those with allelic deletions on chromosome 13, showed normal RB nuclear protein staining patterns. We conclude that loss of RB expression is not a frequent event in primary ovarian carcinomas and that this gene is probably not the target of the frequent allelic deletions on chromosome 13 found in high grade ovarian carcinomas.